Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms
- PMID: 31125275
- DOI: 10.1096/fj.201900319R
Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms
Abstract
NK cells have an important role in immunosurveillance of multiple myeloma (MM) progression, and their activity is enhanced by combination therapies able to regulate the expression of specific activating ligands. Liver X receptors (LXRs) are nuclear receptors and important regulators of intracellular cholesterol and lipid homeostasis. Moreover, they have regulatory roles in both cancer and immune response. Indeed, they can regulate inflammation and innate and acquired immunity. Furthermore, LXR activation directly acts in cancer cells (e.g., prostate, breast, melanoma, colon cancer, hepatocarcinoma, glioblastoma, and MM) that show an accumulation of cholesterol and alteration of LXR-mediated metabolic pathways. Here, we investigated the role of LXR and cholesterol on the expression of the NK cell-activating ligands major histocompatibility complex class I chain-related molecule A and B (MICA and MICB) in MM cells. The results shown in this work indicate that MM cells are responsive to LXR activation, which induces changes in the intracellular cholesterol content. These changes correlate with an enhanced expression of MICA and MICB in human MM cell lines and in primary malignant plasma cells, 2 ligands of the NK group 2D receptor (NKG2D)/CD314 activating receptor expressed in cytotoxic lymphocytes, rendering MM cells more sensitive to recognition, degranulation, and killing by NK cells. Mechanistically, we observed that LXR activation regulates MICA and MICB expression at different levels: MICA at the transcriptional level, enhancing mica promoter activity, and MICB by inhibiting its degradation in lysosomes. The present study provides evidence that activation of LXR, by enhancing NKG2D ligand expression, can promote NK cell-mediated cytotoxicity and suggests a novel immune-mediated mechanism involving modulation of intracellular cholesterol levels in cancer cells.-Bilotta, M. T., Abruzzese, M. P., Molfetta, R., Scarno, G., Fionda, C., Zingoni, A., Soriani, A., Garofalo, T., Petrucci, M. T., Ricciardi, M. R., Paolini, R., Santoni, A., Cippitelli, M. Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.
Keywords: LXR; cholesterol; natural killer.
Similar articles
-
Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.J Immunol. 2009 Oct 1;183(7):4385-94. doi: 10.4049/jimmunol.0901797. Epub 2009 Sep 11. J Immunol. 2009. PMID: 19748980
-
Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.Cell Death Dis. 2021 Sep 4;12(9):836. doi: 10.1038/s41419-021-04104-w. Cell Death Dis. 2021. PMID: 34482362 Free PMC article.
-
Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.J Hematol Oncol. 2016 Dec 1;9(1):134. doi: 10.1186/s13045-016-0362-2. J Hematol Oncol. 2016. PMID: 27903272 Free PMC article.
-
Targeting NKG2D/NKG2DL axis in multiple myeloma therapy.Cytokine Growth Factor Rev. 2024 Apr;76:1-11. doi: 10.1016/j.cytogfr.2024.02.001. Epub 2024 Feb 15. Cytokine Growth Factor Rev. 2024. PMID: 38378397 Review.
-
Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation.Front Immunol. 2021 Mar 30;12:651751. doi: 10.3389/fimmu.2021.651751. eCollection 2021. Front Immunol. 2021. PMID: 33868289 Free PMC article. Review.
Cited by
-
Lipid metabolism alteration contributes to and maintains the properties of cancer stem cells.Theranostics. 2020 May 30;10(16):7053-7069. doi: 10.7150/thno.41388. eCollection 2020. Theranostics. 2020. PMID: 32641978 Free PMC article. Review.
-
Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?Front Immunol. 2020 Feb 21;11:275. doi: 10.3389/fimmu.2020.00275. eCollection 2020. Front Immunol. 2020. PMID: 32153582 Free PMC article. Review.
-
Lipid metabolic vulnerabilities of multiple myeloma.Clin Exp Med. 2023 Nov;23(7):3373-3390. doi: 10.1007/s10238-023-01174-2. Epub 2023 Aug 28. Clin Exp Med. 2023. PMID: 37639069 Free PMC article. Review.
-
Proteome-wide association studies for blood lipids and comparison with transcriptome-wide association studies.HGG Adv. 2025 Jan 9;6(1):100383. doi: 10.1016/j.xhgg.2024.100383. Epub 2024 Nov 14. HGG Adv. 2025. PMID: 39543875 Free PMC article.
-
Recent advances in novel tumor immunotherapy strategies based on regulating the tumor microenvironment and immune checkpoints.Front Immunol. 2025 Jun 18;16:1529403. doi: 10.3389/fimmu.2025.1529403. eCollection 2025. Front Immunol. 2025. PMID: 40607438 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical